Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) reported FCF Margin of 16.87% for Q1 2026, up 5766.0% on a YoY basis from 0.29% in Q1 2025, and up 3.92% quarter-over-quarter from 16.23% in Q4 2025.
Zevra Therapeutics (ZVRA) FCF Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics has reported FCF Margin for 8 years, with the latest figure at 16.87% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 5766.0% year-over-year to 16.87%; the trailing twelve-month figure through Mar 2026 stood at 9.81% (up 16242.0% YoY), and the FY2025 full-year result was 2.29%, up 29276.0% from the prior year.
- FCF Margin for Q1 2026 stood at 16.87%, up from 16.23% in the prior quarter.
- The five-year high for FCF Margin was 16.87% in Q1 2026, with the low at 8581.25% in Q2 2022.
- Historically, FCF Margin has averaged 657.18% across 5 years, with a median of 128.27% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 871962 bps — and 2023, when it soared 847822 bps.
- Zevra Therapeutics' FCF Margin stood at 205.02% in 2022, then jumped by 39 bps to 125.62% in 2023, then fell by 8 bps to 135.28% in 2024, then soared by 112 bps to 16.23% in 2025, then grew by 4 bps to 16.87% in 2026.
- The last three FCF Margin figures came in at 16.87% (Q1 2026), 16.23% (Q4 2025), and 15.94% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 16.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.87% |
| Dec 31, 2025 | 16.23% |
| Sep 30, 2025 | 15.94% |
| Jun 30, 2025 | -14.74% |
| Mar 31, 2025 | -40.79% |
| Dec 31, 2024 | -135.28% |
| Sep 30, 2024 | -490.96% |
| Jun 30, 2024 | -434.30% |
| Mar 31, 2024 | -475.44% |
| Dec 31, 2023 | -125.62% |
| Sep 30, 2023 | -165.80% |
| Jun 30, 2023 | -103.03% |
| Mar 31, 2023 | -128.27% |
| Dec 31, 2022 | -205.02% |
| Sep 30, 2022 | -230.55% |
| Jun 30, 2022 | -8,581.25% |
| Mar 31, 2022 | -90.01% |
| Dec 31, 2021 | -33.50% |
| Sep 30, 2021 | -142.14% |
| Jun 30, 2021 | 138.37% |